Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: Results of a study in a primary care setting

Table 1 Characteristics of the intention-to-diagnose population in the placebo and rabeprazole groups (n, mean ± SD)

	Placebo(n = 39)	Rabeprazole(n = 33)	Pvalue
Men/women (%)	46/54	33/67	0.269
Mean age (yr)(mean ± SD)	47.1±11.8	49.1±11.9	0.4
BMI (kg/m2) (mean ± SD)	25.6 ± 4.4	26.1±5.2	0.8
Smoker (%)	17.9	30.3	0.219
Previous endoscopy (%)	33.3	30.3	0.783
Time from first symptoms1 (mo)	24.3 ± 51.5	20.2 ± 27.0	0.956
Post-prandial symptoms (%)	30.8	33.3	0.232
Nocturnal symptoms (%)	12.8	15.1	0.232
Hiatus hernia (%)	47.4	27.3	0.082
Esophagitis (%)	30.8	33.3	0.816
Barrett's oesophagus (%)	2.6	6.1	0.474
Diagnosis of GERD2 (%)	67.6	62.1	0.642

¹Suggesting the possibility of GERD;

²Established by the presence of esophagitis and/or pathological exposure to acid during the 24-h period and/or significant association between symptoms and reflux.